Mereo BioPharma Investors Urged to Act Before Securities Class Action Deadline Arrives

Urgent Reminder for Mereo BioPharma Investors

As the deadline approaches for a significant securities class action, investors in Mereo BioPharma Group plc are urged to be proactive regarding their legal options. Faruqi & Faruqi, LLP, a reputable securities law firm, is spearheading an investigation into the company and reminds shareholders that they must act before April 6, 2026, to potentially assume the role of lead plaintiff in the case.

The legal firm is focusing on claims arising from the company’s alleged failure to adhere to federal securities laws due to misleading statements concerning its Phase 3 ORBIT and COSMIC programs. Both studies failed to meet key primary endpoints intended to reduce clinical fracture rates, which may have had a monumental impact on share prices and investor confidence.

On December 29, 2025, Mereo disclosed that the results from these critical trials were underwhelming, resulting in a staggering loss of $2.02 per share, translating to an 87.64% decrease, with closing shares plummeting to $0.28 each. This represents a significant decline in value and raises important questions regarding the integrity of information provided by the company to its investors.

James (Josh) Wilson, a partner at Faruqi & Faruqi, is leading the investigation and is encouraging affected investors to reach out directly. He highlighted the importance of making informed decisions during this period, noting that those who acquired Mereo securities between June 5, 2023, and December 26, 2025, have a unique opportunity to address their losses through this legal avenue.

It’s essential for investors to understand that those wishing to become lead plaintiffs must be among those with the largest financial interests, who also align with the interests of the broader investor class. If you choose to remain an absent class member, your eligibility for potential recovery remains intact, regardless of your active participation in the litigation.

Faruqi & Faruqi is known for its strong track record, recovering hundreds of millions of dollars in investor claims since its establishment in 1995. With offices across several states, including New York, Pennsylvania, California, and Georgia, the firm is well-equipped to assist affected investors through this challenging process.

In addition to reaching out to the firm, shareholders and whistleblowers with substantial information about Mereo’s practices during the relevant time frame are encouraged to come forward. Legal experts at Faruqi & Faruqi are prepared to navigate these complexities and ensure the interests of investors are protected.

For the latest updates and detailed information on Mereo BioPharma’s class action litigation, interested parties can visit Faruqi & Faruqi’s website or contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

In conclusion, the urgency of this situation cannot be overstated. All affected investors should consider their options carefully and take necessary action before the April 6, 2026, deadline.